Business Wire

Vedanta Aluminium Launches ‘Restora’, First Low Carbon ‘Green’ Aluminium from India

Share

Vedanta Aluminium, India’s largest producer of aluminium and value-added products, launches ‘Restora’, its low carbon, ‘green’ aluminium brand, under which it unveiled two product lines – Restora (low carbon aluminium) and Restora Ultra (ultra-low carbon aluminium). Vedanta is the first Indian aluminium producer to manufacture products for addressing the fast-growing global demand for low carbon aluminium, driven by greater climate consciousness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005673/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vedanta Aluminium launches Restora low carbon green aluminium (Photo: Business Wire)

Manufactured using renewable energy, Restora’s GHG emission intensity is well below 4 tonnes of CO2 equivalent per tonne of aluminium manufactured – the global threshold for aluminium to be considered as low carbon aluminium, as per assessment by an independent, global verification assurance firm. Restora Ultra, manufactured with aluminium recovered from dross (a by-product of the aluminium smelting process), has a near-zero carbon footprint that is amongst the lowest in the world. For this, Vedanta has partnered with Runaya Refining, a fast-growing manufacturing start-up focussed on creating innovative solutions for the resources sector. Vedanta Aluminium can customize Restora into ingots, billets and other value-added products, as per customer requirements.

Rahul Sharma, CEO – Aluminium Business, Vedanta Ltd., said, “The launch of Restora marks a proud moment in our commitment to decarbonize our operations and provide our customers an unmatched competitive advantage with sustainable aluminium products. Restora has a GHG emission intensity which is almost half of the global threshold for low carbon aluminium. With consumers becoming increasingly conscious of the provenance of the products they use, Vedanta’s Restora will provide them the assurance that the aluminium they purchase has amongst the lowest carbon footprints in the world.”

Annanya Agarwal, co-founder, Runaya, added, “We are delighted to collaborate with Vedanta for creating Restora Ultra. Runaya is working towards disrupting the linear economy model by building in principles of circularity and sustainability into the design of the resources industry.”

Vedanta Aluminium Business, a division of Vedanta Limited, is India’s largest manufacturer of aluminium, producing 1.97 million tonnes per annum (MTPA) in FY21. The company ranked 4th among aluminium producers globally in the Dow Jones Sustainability Index (DJSI) in 2021. The company is on a mission to spur emerging applications of aluminium as the ‘Metal of the Future’ for a greener tomorrow.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sonal Choithani
Chief Communication Officer
Vedanta Limited – Aluminium Business
Email: Sonal.Choithani@vedanta.co.in
www.vedantaaluminium.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom